Oncology CME Courses

Credits: 1.0 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: May 12, 2016
Expiration Date: May 12, 2018
Summary:

Acute lymphoblastic leukemia (ALL) is one of a group of malignancies caused by cytogenetic DNA mutations of developing hematopoietic stem cell precursors and mostly common to children with peak incidence at 2-5 years of age. Although approximately 80% of ALL cases present in children, they also occur in adults.  The symptoms of ALL are non-specific and similar to those of acute myelogenous leukemia (AML), which patients usually have 1-3 months of complaints.

By the end of the session the participant will be able to:

  • Summarize the most impactful findings presented at ASH 2015 relating to ALL and apply them to patient cases, taking into account any relevant barriers to care.
  • Additional objectives to be dictated by clinical content
Credits: 2 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: 9/29/2017
Expiration Date: 9/29/2018
Summary:
Credits: 1 (AMA PRA Category 1)
Format: Online Streaming Video, PDF, Online Download, Interactive Online
Price: Free
Release Date: October 19, 2017
Expiration Date: October 19, 2019
Summary:

Colorectal cancer (CRC) is the third-leading cause of cancer deaths in the U.S. While a majority of patients are diagnosed before their disease has metastasized, a fifth of patients have advanced disease at the time of diagnosis. Early detection and screening have been shown to significantly reduce CRC mortality, and screening is widely recommended for average-risk adults beginning at age 50 years, (as well as earlier for individuals at higher risk). Since the mid-1990s, the U.S. Preventive Services Task Force, American Cancer Society, and other groups have recommended several modalities for screening: fecal occult blood testing (FOBT), flexible sigmoidoscopy, colonoscopy, and barium enema. Recent years have seen the addition of newer screening technologies, including stool DNA, computed tomographic colonography, and capsule endoscopy.

By the end of the session the participant will be able to:

  • Describe present the current practice guideline recommendations with respect to colorectal cancer screening, including colonoscopy preparation, and apply them to patient cases
  • Identify the treatment modalities currently available for management of mCRC and apply them to patient cases using evidence-based medicine
  • Evaluate a treatment plan for a specific patient with mCRC to optimize safety, efficacy, and tolerability, suggesting modifications for improvement
  • Describe the challenges and barriers to care associated with treating patients with mCRC
Credits: 1 (AMA PRA Category 1)
Format: Interactive Online, Online Streaming Video, PDF
Price: Free
Release Date: November 02, 2017
Expiration Date: November 02, 2019
Summary:

Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. Helping the clinician discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies – among others – based on the most up-to-date research merits continuing education programming in MM.

By the end of the session the participant will be able to:

  • Recall updates in the staging, prognosis, and diagnosis of MM.
  • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
  • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.
Credits: 1 (AMA PRA Category 1)
Format: Interactive Online
Price: Free
Expiration Date: 6/14/18
Summary:
Credits: 1.25 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: Dec 4, 2017
Expiration Date: Dec 4, 2019
Summary:

By the end of the session the participant will be able to:

  • Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
  • Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Describe emerging (investigational) therapies for metastatic melanoma
  • Describe the challenges and barriers to care associated with treating patients with metastatic melanoma
Credits: 1 (AMA PRA Category 1)
Format: Online Publication
Price: Free
Release Date: 9/19/2017
Expiration Date: 9/19/2019
Summary:

Learning Objectives:

  • Summarize the most impactful findings presented at ASCO 2017 relating to Metastatic Melanoma and apply them to patient cases, taking into account any relevant barriers to care.
  • Additional objectives to be dictated by clinical content
Credits: 0.75 (CE)
Format: Online Streaming Video, Interactive Online, Multiple Formats
Price: Free
Release Date: Nov 17, 2017
Expiration Date: Nov 17, 2019
Summary:
Credits: 1 (AMA PRA Category 1)
Format: Online Streaming Video, Multiple Formats
Price: Free
Release Date: Nov 1, 2017
Expiration Date: April 20, 2018
Summary:

Includes Topics in

  • HR deficiencies and BRCA mutations
  • Recurrent ovarian cancer
  • Data on available and emerging PARP inhibitors
  • Personalizing treatment selection
  • Companion Diagnostics
Credits: 1 (AMA PRA Category 1)
Format: Online Streaming Video, Multiple Formats, Interactive Online
Price: Free
Release Date: Feb 24, 2019
Expiration Date: Feb 24, 2021
Summary:

By the end of the session the participant will be able to:



  • Apply existing guideline recommendations in the diagnosis of HCC
  • Identify present and emerging pharmacotherapeutic treatments for management of unresectable HCC and apply them to patient cases using evidence-based medicine.
  • Describe how to manage challenges that arise during treatment with present and emerging pharmacotherapeutic treatments for HCC, including adverse effect management, and apply that knowledge to a patient case
  • Describe the challenges associated with treating patients with HCC, focusing specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents used to treat the disease, and apply that information in optimizing patient care in a patient case
Credits: 1.25 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: Dec 4, 2017
Expiration Date: Dec 4, 2019
Summary:

By the end of the session the participant will be able to:

  • Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
  • Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Describe emerging (investigational) therapies for metastatic melanoma
  • Describe the challenges and barriers to care associated with treating patients with metastatic melanoma